Parkinson's Disease is NOT a Contraindication for Either TMS or Spravato
Neither transcranial magnetic stimulation (TMS) nor esketamine nasal spray (Spravato) lists Parkinson's disease as a contraindication, and both can be safely used in PD patients with appropriate monitoring.
Spravato (Esketamine) and Parkinson's Disease
The FDA-approved contraindications for Spravato are explicitly limited to 1:
- Aneurysmal vascular disease or arteriovenous malformation
- History of intracerebral hemorrhage
- Hypersensitivity to esketamine or ketamine
Parkinson's disease is notably absent from this list. The 2022 VA/DoD guidelines for major depressive disorder recommend ketamine or esketamine for treatment-resistant depression without mentioning PD as a contraindication 2. The primary safety concerns with Spravato relate to blood pressure elevation (requiring 2-hour post-dose monitoring), cognitive impairment, and sedation—none of which are PD-specific contraindications 1.
Key Monitoring Requirements for Spravato in PD Patients:
- Blood pressure monitoring for at least 2 hours post-administration
- Assessment around 40 minutes post-dose when BP peaks
- Patients cannot drive for at least 6-8 hours after treatment
- REMS program certification required for administration sites
TMS and Parkinson's Disease
TMS is not only safe in Parkinson's disease but has been extensively studied as both a diagnostic tool and therapeutic intervention in this population. Multiple comprehensive reviews confirm excellent safety profiles 3, 4, 5, 6.
Safety Evidence:
A systematic literature review of TMS in PD patients identified 3:
- 84 single/paired-pulse TMS studies involving 1,091 PD patients: Risk of adverse events was 0.0018 per patient (95% CI: 0.0002-0.0066) with zero seizures
- 77 repetitive TMS studies involving 1,137 PD patients: Risk of adverse events was 0.040 per patient (95% CI: 0.029-0.053) with zero seizures
The only adverse events reported were minor and transient: headaches, scalp pain, tinnitus, nausea, and muscle jerks. One study noted transient worsening of parkinsonian symptoms with rTMS over the supplementary motor area, but this was temporary 3.
Important Caveat - Deep Brain Stimulation:
The only scenario requiring extreme caution is combining TMS with deep brain stimulation (DBS). If a PD patient has implanted DBS leads, TMS can induce potentially dangerous currents in the conductive leads, causing over-stimulation 7. This combination has not been approved and should be avoided unless part of a carefully controlled research protocol.
TMS Applications in PD:
Recent evidence demonstrates TMS is actively used in PD for 4, 5, 6, 8:
- Diagnostic neurophysiological assessment
- Therapeutic modulation of motor symptoms (bradykinesia, rigidity)
- Treatment of non-motor symptoms (mood, cognition)
- High-frequency rTMS over primary motor cortex shows moderate efficacy
Clinical Decision Algorithm
For Spravato:
- Screen for actual contraindications (vascular malformations, intracerebral hemorrhage history, hypersensitivity)
- If PD patient has treatment-resistant depression → Spravato is appropriate
- Ensure BP monitoring capability and REMS-certified facility
- Arrange transportation (no driving for 6-8 hours)
For TMS:
- Confirm patient does NOT have implanted DBS leads (absolute contraindication to combination)
- If no DBS → TMS is safe and may provide therapeutic benefit
- Follow standard TMS safety guidelines (no additional PD-specific precautions needed) 3
- Consider high-frequency rTMS over M1 for motor symptoms
Common Pitfall to Avoid
Do not confuse the presence of Parkinson's disease with the actual contraindications for these treatments. The evidence is clear that PD itself does not preclude use of either modality. The only absolute contraindication is the combination of TMS with existing DBS hardware 7.